Rosiglitazone

CHEMBL121 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

357.4 g/mol

LogP

3.1

Phase

4

A thiazolidinedione insulin sensitizer used to treat type 2 diabetes by making the body's cells more responsive to insulin, reducing blood glucose levels. Its use has become restricted in many countries due to concerns about increased cardiovascular risk, particularly heart failure.

Molekularmasse

357,4000 g/mol

LogP

3,10

TPSA

96,80 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Schizophrenia Bipolar Disorder Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Hyperlipidemia Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Malaria HIV/AIDS Hepatitis C Heart Failure Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1

InChI

InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)

Molecular Formula

C18H19N3O3S

HBD / HBA

1 / 6

Rotierbare Bindungen

7

Schwere Atome

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A thiazolidinedione insulin sensitizer used to treat type 2 diabetes by making the body's cells more responsive to insulin, reducing blood glucose levels. Its use has become restricted in many countries due to concerns about increased cardiovascular risk, particularly heart failure.

Yes, Rosiglitazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL121. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 77999. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Rosiglitazone auf PillFYI

Struktur

Schnelldaten

Formel: C18H19N3O3S
Synonyme: 2

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.